Open an account

Immunic

IMUX · NASDAQ

$7.41+$0.42 (+6.01%)TodayMarket closed ·
Prev close $6.99

About IMUX

Immunic Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2014-04-17. Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Employees
92
Headquarters
New York City, New York
Listed
Apr 17, 2014
Sector
Health Care
Industry
Biotechnology
Website
imux.com

IMUX key statistics

Market cap
101.11M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
447.28K
Volume
429.68K
Open price
$6.99
High today
$7.64
Low today
$6.95
52 Week high
$17.43
52 Week low
$5.06

Immunic (IMUX) at a glance

Immunic (IMUX) last traded at $7.41, with a market cap of 101.11M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.95 and $7.64. The current price is 6.6% above the day's low and 3.0% below its high.

Volume so far is 429.68K shares, in line with the average of 447.28K shares a day.

Over the past year Immunic has ranged from $5.06 to $17.43, and now sits 19% of the way up that range.

Immunic met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.80 per share against an estimate of -$1.22.

The average analyst price target is $43.95, 493.2% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

83%of 6 analyst ratings say Buy
  • Buy83.3%
  • Hold16.7%
  • Sell0.0%
Price target · 13 analystsAvg $43.95
Low
$22.22
Now
$7.41
High
$89.25

IMUX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 28.4% on average.

  1. Q3 FY24: reported -$2.40 per share against an estimate of -$2.22
  2. Q4 FY24: reported -$2.50 per share against an estimate of -$2.41
  3. Q1 FY25: reported -$2.50 per share against an estimate of -$2.41
  4. Q2 FY25: reported -$2.00 per share against an estimate of -$1.68
  5. Q3 FY25: reported -$1.30 per share against an estimate of -$1.71
  6. Q4 FY25: reported -$0.70 per share against an estimate of -$0.9601
  7. Q1 FY26: reported -$1.08 per share against an estimate of -$0.9308
  8. Q2 FY26: reported -$0.80 per share against an estimate of -$1.22

IMUX news

  • Press releasePRNewswire

    Immunic Appoints Jaa Roberson as Chief People Officer

  • Press releasePRNewswire

    Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

  • Press releasePRNewswire

    Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

  • Press releasePRNewswire

    Immunic Appoints Chitrang Davé as Chief Data and Digital Officer

  • Press releasePRNewswire

    Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  • Press releasePRNewswire

    Immunic Appoints Elena Ridloff to Board of Directors

  • Press releasePRNewswire

    Immunic to Participate in Investor Conferences in July

  • Press releasePRNewswire

    Immunic to Participate in Investor, Industry and Scientific Conferences in June

Similar companies

Companies in the same industry as Immunic

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.